The business case for vaccine and drug manufacturing in middle-income countries
Lancet Glob Health
.
2022 Jul;10(7):e944-e945.
doi: 10.1016/S2214-109X(22)00249-2.
Author
Lenias Hwenda
1
Affiliation
1
Access to Medicines, Medicines for Africa, Bryanston 2191, South Africa. Electronic address: lenias@medicines4africa.com.
PMID:
35714638
DOI:
10.1016/S2214-109X(22)00249-2
No abstract available
Publication types
Comment
MeSH terms
Commerce
Developing Countries*
Humans
Income
Vaccines*
Substances
Vaccines